These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24395449)

  • 1. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?
    Bevan CJ; Cree BA
    JAMA Neurol; 2014 Mar; 71(3):269-70. PubMed ID: 24395449
    [No Abstract]   [Full Text] [Related]  

  • 2. [The research hot points on multiple sclerosis].
    Xu XH; Liu JJ
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2737-8. PubMed ID: 18167260
    [No Abstract]   [Full Text] [Related]  

  • 3. Setting the agenda for multiple sclerosis rehabilitation research.
    Mayo N
    Mult Scler; 2008 Nov; 14(9):1154-6. PubMed ID: 18952830
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacogenetics of autoimmune diseases: research issues in the case of Multiple Sclerosis and the role of IFN-beta.
    Macciardi F; Martinelli Boneschi F; Cohen D
    J Autoimmun; 2005; 25 Suppl():1-5. PubMed ID: 16311019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A much-needed focus on progression in multiple sclerosis.
    Thompson AJ
    Lancet Neurol; 2015 Feb; 14(2):133-5. PubMed ID: 25772885
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical consequences of MRI activity in treated multiple sclerosis.
    Cadavid D; Kim S; Peng B; Skurnick J; Younes M; Hill J; Wolansky LJ; Cook SD
    Mult Scler; 2011 Sep; 17(9):1113-21. PubMed ID: 21613336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis: long-term remission after a high dose of cyclophosphamide.
    de Bittencourt PR; Gomes-da-Silva MM
    Acta Neurol Scand; 2005 Mar; 111(3):195-8. PubMed ID: 15691289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Setting the agenda for multiple sclerosis rehabilitation research.
    Kraft GH; Johnson KL; Yorkston K; Amtmann D; Bamer A; Bombardier C; Ehde D; Fraser R; Starks H
    Mult Scler; 2008 Nov; 14(9):1292-7. PubMed ID: 18632785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis clinical trials: old and new challenges.
    Noseworthy JH
    Semin Neurol; 1998; 18(3):377-88. PubMed ID: 9817540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A plea for "omics" research in complex diseases such as multiple sclerosis--a change of mind is needed.
    Martin R; Leppert D
    J Neurol Sci; 2004 Jul; 222(1-2):3-5. PubMed ID: 15240188
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravenous methylprednisolone for exacerbations in multiple sclerosis.
    Woolf K
    Medsurg Nurs; 1995 Jun; 4(3):207-10. PubMed ID: 7780474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. We are about to cure multiple sclerosis in the next 10 years, even though we do not know its cause: yes.
    Scolding N
    Mult Scler; 2012 Jun; 18(6):782-3. PubMed ID: 22619225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MS treatment: postmarketing studies.
    Montalban X
    J Neurol Sci; 2007 Aug; 259(1-2):42-5. PubMed ID: 17383679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sustained clinical remission in a patient with remittent-recurrent multiple sclerosis and celiac disease gluten-free diet for 6 years].
    Hernández-Lahoz C; Rodríguez S; Tuñón A; Saiz A; Santamarta E; Rodrigo L
    Neurologia; 2009 Apr; 24(3):213-5. PubMed ID: 19418302
    [No Abstract]   [Full Text] [Related]  

  • 15. [New approaches in research of therapy of multiple sclerosis].
    Hemmer B; Cepok S; Nessler S; Sommer N
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():23-8. PubMed ID: 11603112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the "ABCNR" drugs in multiple sclerosis.
    Mattson DH
    Semin Neurol; 2002 Mar; 22(1):17-25. PubMed ID: 12170390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: yes.
    Havrdová E
    Mult Scler; 2012 Sep; 18(9):1209-10. PubMed ID: 22936682
    [No Abstract]   [Full Text] [Related]  

  • 18. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. We are about to cure MS in the next 10 years, even though we do not know its cause: no.
    Coles A
    Mult Scler; 2012 Jun; 18(6):784-5. PubMed ID: 22619226
    [No Abstract]   [Full Text] [Related]  

  • 20. Biogen Idec restructures, sharpens neurology focus.
    Mitchell P
    Nat Biotechnol; 2011 Jan; 29(1):7-8. PubMed ID: 21221080
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.